Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 29

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 29
---
Description of Debt Securities — Limitation on Liens” and “Description of Debt Securities — Merger, Consolidation, or Sale of Assets” in the accompanying prospectus.

<div align='center'>S-14</div>

TABLE OF CONTENTS

Application will be made for the notes to be admitted to the Official List of Euronext Dublin and to trading on the Global Exchange Market thereof. The listing application will be subject to approval by Euronext Dublin. The Global Exchange Market is not a regulated market within the meaning of MiFID II.

#### Guarantee
Boston Scientific will fully and unconditionally guarantee the due and punctual payment of principal of and premium, if any, and interest on the notes on a senior unsecured basis, when and as the same become due and payable, whether on a maturity date, by declaration of acceleration, upon redemption, repurchase or otherwise, and all other obligations of the issuer under the indenture and the notes.

The obligations of Boston Scientific under its guarantees of the debt securities will be limited as necessary to prevent such guarantees from constituting a fraudulent conveyance or fraudulent transfer under applicable law; this limitation, however, may not be effective to prevent such guarantees from constituting a fraudulent conveyance.

#### Ranking
The notes will be senior unsecured obligations of AMS Europe, will rank equally in right of payment with all of AMS Europe’s other existing and future unsecured and unsubordinated indebtedness and be senior to any future indebtedness of AMS Europe that is subordinated to the notes. All of AMS Europe’s obligations under the notes will be fully and unconditionally guaranteed by Boston Scientific, AMS Europe’s ultimate parent company, on a senior unsecured basis (the “guarantees”). The guarantees will rank equally in right of payment with all of Boston Scientific’s other existing and future unsecured and unsubordinated indebtedness and be senior to any future indebtedness of Boston Scientific that is subordinated to the guarantees. The notes and the guarantees will be effectively junior to any future secured indebtedness of AMS Europe and Boston Scientific, respectively, to the extent of the collateral securing such indebtedness, and be structurally junior to any existing and future indebtedness and other liabilities of Boston Scientific’s subsidiaries (other than AMS Europe). At December 31, 2024, Boston Scientific had outstanding approximately $10,746 million of unsecured indebtedness and no secured indebtedness. In addition, certain of Boston Scientific’s subsidiaries had approximately $175 million of outstanding indebtedness at December 31, 2024 that